German China

3D ex vivo Microfluidics Platform

Beyond Limitations: New Microfluidics Platform for Cancer Drug Screening and Profiling

Page: 3/3

Related Vendor


[1] Hirschhaeuser F. Menne H. Dittfeld C. et al. (2010). Multicellular tumor spheroids: an underestimated tool is catching up again. Jour of Biotechno, 148(1), 3–15.

[2] Durand RE (1984). Growth and cellular characteristics of multicell spheroids. Recent Results Can Res. 95:24-49.

[3] Cukierman E, Pankov R, Stevens DR, Yamada KM (2001). Taking cell-matrix adhesions to be the third dimension. Science. 294:1708-12.

[4] Mizushima H, Wang X, Miyamoto S, Mekada E (2009). Integrin signal masks growth promoting activity of HB-EGF in monolayer cell cultures. J Cell Sci. 122:4277-86.

[5] Kondo J, Endo H, Okuyama H, Ishikawa O. et al. (2011). Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci . Apr 12;108 (15):6235-40.

[6] Yoshii Y, Furukawa T, Waki A, Okuyama H, Inuoue M, Itoh M et al. (2015). High-throughput screening with nanoimprinting 3D culture for efficient drug development by mimicking the tumor environment. Biomaterials 5:278-89.

[7] Sun Y, Campisi J, Higano, C. Beer TM. et al. (2012). Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Sep;18 (9):1359-68.

[8] Morikawa, T. Shee, K. et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Jul 26;487 (7408):500-4.

[9] Wilson TR, Fridlyand J, Yan Y, Burton L. et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Jul 26; 487(7408):505-9.

[10] Ostman A (2012). The tumor microenvironment controls drug sensitivity. Sep;18 (9):1332-4.

[11] Harris AL (2002). Hypoxia-a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 38-47.

[12] Mellor HR & Callaghan R (2008). Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology, 81, 275-300.

[13] Sahin AA, R JY, el-Naggar AK, Wilson PL et al. (1991). Tumor proliferative fraction in solid malignant neoplasms. A comparative study of ki67 immunostaining and flow cytometric determination. Am J Clin Pathol. 96, 512-519.

[14] St Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N et al.(1996). Impact of the cclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2, 1204-1210.

[15] Gardener L.B. et al. (2001). Hypoxia inhibitsG1/S transition through regulation of p27expression. J. Biol. Chem. 276, 7919-7926.

[16] Desoize B, Jardillier J. (2000). Multicellular resistance: a paradigm for clinical resistance? Cri Rev Oncol Hematol, Nov-Dec; 36 (2-3): 193-197.

[17] Terrell-Hall TB, Nounou MI, El-Amrawy F, Griffith JIG, Lockman PR. (2017).Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. Oncotarget. Jul 26;8(48): 83734-83744.

[18] Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L. (2017). Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform. BMC Cancer. Nov 2;17(1):709.

[19] Yin X, Mead, E.B, Safaee H, Langer R, Karp JM. (2016). Engineering Stem Cell Organoids. Cell Stem Cell, January 7 (18): 25-38.

[20] Boussomier-Calleja A, Li R, Chen MB, Wong SC and Kamm RD. (2016). Microfluidics: A new tool for modelling cancer.immune interactions. Trends Cancer. January 1;2(1): 6-19.

* S. Dhar, A. Sim: AMS Biotechnology Ltd, Abingdon, OX14 4SE, United Kingdom

* * T. Mullholand, G. Robertson, M. Zagnoni: Center for Microsystems & Photonics, Dept. Electronic and Electric Engineering, University of Strathclyde, Royal College Building, Glasgow G1 1XW, United Kingdom